<DOC>
	<DOCNO>NCT00661739</DOCNO>
	<brief_summary>The aim study establish feasible combination bendamustine paclitaxel weekly schedule . The two agent different toxicity profile well tolerate give weekly fashion . The combination might special interest elderly patient hormone insensitive breast cancer</brief_summary>
	<brief_title>A Multicentre Phase I-II Study Investigate Combination Bendamustine With Weekly Paclitaxel First Second Line Therapy Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Written informed consent must obtain document accord local regulatory requirement prior begin specific protocol procedure ; Pathological confirm primary carcinoma breast . Locally advanced metastatic disease Up one previous palliative chemotherapy contain docetaxel paclitaxel . Previous adjuvant treatment taxanes allow last application taxane give least 1 year enter trial . Patients must either measurable nonmeasurable lesion accord WHO criteria At least 4 week since radiotherapy , full recovery . The measurable disease must completely outside radiated field must pathological proof progressive disease . Complete radiological clinical tumor assessment within 4 week prior registration perform clinically indicate KarnofskyIndex ≥ 60 % Age ≥ 18 year Absolute neutrophil count ≥ 1,500 cells/µl , platelet ≥ 100,000/µl , hemoglobin ≥ 9 g/dl Bilirubin within normal limit ; evaluation transaminases alkaline phosphatase ≤ 5x upper normal limit Serum creatinine ≤ 2.0 mg/dl Normal leave ventricular ejection fraction ( LVEF ) echocardiogramme Patients childbearing potential , pregnancy test must negative If fertile effective contraception must use throughout study Known suspect hypersensitivity reaction investigational compound incorporated substance ; Concurrent immunotherapy hormonal treatment cancer ( Bisphosphonates may continue ) Symptomatic parenchymal brain metastasis respond treatment Life expectancy le 3 month Other serious illness medical condition may interfere understand give informed consent conduct study Concurrent treatment experimental drug anticancer therapy within last 28 day ; History congestive heart failure significant uncontrolled cardiac disease Pregnant nursing woman</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>palliative</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>Bendamustine</keyword>
	<keyword>phase I</keyword>
</DOC>